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Abstract
Background: Searching for new effective drugs against human and animal toxoplasmosis we decided to test the
anti-Toxoplasma potential of phytoecdysteroids (α-ecdysone and 20-hydroxyecdysone) characterized by the
pleiotropic activity on mammalian organisms including the enhancement of host’s anti-parasitic defence. This
objective was accomplished by the in vitro evaluation of T. gondii growth in phytoecdysteroid-treated
immunocompetent cells of selected hosts: humans and two strains of inbred mice with genetically determined
different susceptibility to toxoplasmosis.
Methods: Peripheral mononuclear blood cells were isolated from Toxoplasma-positive and Toxoplasma-negative
women (N = 43) and men (N = 21). Non-infected mice (C57BL/6, N = 10 and BALB/c, N = 14) and mice (BALB/c, N = 10)
challenged intraperitoneally with 5 tissue cysts of the T. gondii DX strain were also used in this study as a source of
splenocytes. The effects of phytoecdysteroids on the viability of human PBMC and mouse splenocytes were evaluated
using the MTT assay. The influence of phytoecdysteroids on PBMCs, splenocytes and T. gondii proliferation was
measured using radioactivity tests (the level of 3[H] uracil incorporation by toxoplasms or 3[H] thymidine by PBMCs
and splenocytes), which was confirmed by quantitative Real-Time PCR. Statistical analysis was performed using
SigmaStat 3.5 (Systat Software GmbH). The best-fit IC50 curves were plotted using GraphPad Prism 6.0 (GraphPad
Software, Inc.).
Results: Our results showed that phytoecdysteroids promote the multiplication of Toxoplasma in cultures of human or
murine immune cells, in contrast to another apicomplexan parasite, Babesia gibsoni. Additionally, the tested
phytoecdysteroids did not stimulate the in vitro secretion of the essential protective cytokines (IFN-γ, IL-2 and IL-10),
neither by human nor by murine immune cells involved in an effective intracellular killing of the parasite.
Conclusions: Judging by the effect of phytoecdysteroids on the T. gondii proliferation, demonstrated for the first time
in this study, it seems that these compounds should not be taken into consideration as potential medications to treat
toxoplasmosis. Phytoecdysteroids included in the food are most likely not harmful for human or animal health but
certain nutrients containing ecdysteroids at high concentrations could promote T. gondii proliferation in chronically
infected and immunocompromised individuals. In order to assess the real impact of ecdysteroids on the course of
natural T. gondii invasion, in vivo research should be undertaken because it cannot be ruled out that the in vivo effect
will be different than the in vitro one. However, taking into account the possible stimulating effect of ecdysteroids on
some opportunistic parasites (such as Toxoplasma or Strongyloides) further studies are necessary and should focus on
the mechanisms of their action, which directly or indirectly enhance the parasite growth. Since ecdysteroids are
considered as potential drugs, it is essential to determine their effect on various parasitic pathogens, which may infect
the host at the same time, especially in immunocompromised individuals.
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Background
Toxoplasma gondii is a cosmopolitan intracellular proto-
zoan that causes toxoplasmosis in birds, mammals and
humans. Statistical data concerning the prevalence of
toxoplasmosis indicated that at least one-third of human
population has had contact with this parasite. The high
prevalence of T. gondii infection (e.g., in some parts of
Europe 58–90 %) is related to sex, age, culinary habits,
personal hygiene, condition of the immune system and
dysfunctions of the endocrinal network [1–3]. Despite the
significant progress in the research on the biology of T.
gondii invasion, the proteome of this protozoan and the
immunity it induces, no preventive vaccines for humans
have been developed yet.
T. gondii infection leads to congenital or acquired
postnatal toxoplasmosis characterized by diverse forms
and symptoms. In immunocompetent humans, the infec-
tion is usually asymptomatic as the primary immuno-
logical response quickly limits the parasite replication and
its spreading. Thus, symptomatic toxoplasmosis occurs in-
frequently. Quickly replicating tachyzoites are converted
into bradyzoites and become enclosed in tissue cysts,
which are a sign of chronic toxoplasmosis [4]. Recent
studies demonstrated that a long-term presence of the
parasite is not neutral to the host. It is increasingly often
postulated that there is a causal connection between the
T. gondii carriage and the increased risk of neurologic dis-
eases, such as schizophrenia [5], Parkinson’s disease [6] or
epilepsy [7]. Moreover, a very significant clinical problem
is posed by congenital toxoplasmosis, resulting from the
primary infection of a mother during pregnancy and
transmission of the parasite to a fetus with an immature
immune system. In chronically infected women there is
usually no placental parasite transmission to a fetus,
thus, an especially interesting group for clinicians and
immunoparasitologists are seronegative women at a
child-bearing age, in whom the development of a pri-
mary infection may cause a miscarriage or congenital
defects of the offspring, such as hydrocephaly or micro-
cephaly, chorioretinitis and intracranial calcification,
which constitute the so-called “Sabin-Feldman triad”.
This parasite may also cause serious medical disorders
in humans related to the unchecked proliferation of the
protozoan in immunocompromised patients. A weak-
ened immune system is not able to inhibit the parasite
replication during the reactivation of a latent infection
or the reinvasion by a new strain of a different geno-
type. Uncontrolled T. gondii invasion in such cases can
become a direct cause of death [8, 9].
In the treatment of most clinical forms of toxoplasmo-
sis, the antagonists of folic acid are used: pyrimethamine
in combination with sulfadiazine [10]. Although such ther-
apy is often effective, it may cause multiple side effects,
such as bone marrow suppression, which leads to the
necessity of concurrent administration of folic acid [11].
Additionally, because of the frequent intolerance to sulfa-
diazine, it is often necessary to administer other medica-
tions, e.g., clindamycin or co-trimoxazole. Numerous
drugs used in the treatment of toxoplasmosis cause many
side effects including allergic reactions, leukopenia,
anemia, thrombocytopenia, cardiac dysrhythmia, as well
as digestive tract disorders and skin pigmentation disor-
ders. Hence, searching for less toxic drugs that will effect-
ively act against all life-stages of the parasite is crucial for
the improvement of T. gondii infections treatment.
As current chemotherapy is still not satisfactory, many
attempts are made at developing specific immunoprophy-
laxis (a vaccine that will induce strong protective immun-
ity against toxoplasmosis) [12–14] and obtaining not only
new drugs [15–18] but also alternative therapeutical prep-
arations derived from plants [19, 20]. Such alternative
methods motivate scientists to search for new strategies to
fight toxoplasmosis [3, 21]. Because of the pleiotropic ac-
tivity of phytoecdysteroids on mammalian organisms
(including humans), they gain interest as agents that
potentially enhance the antibacterial, antifungal and an-
tiparasitic activity of host cells. Such studies are still
scarce, however, the obtained results are very promising
and give hope for future application of ecdysteroids in
the chemotherapy of parasitoses. It has been shown
that certain plant extracts are able to suppress the
growth of some Apicomplexa protozoans. For instance,
the infusion of Artemisia annua, rich in artemisinin
and its derivatives, inhibited the proliferation of T. gon-
dii and Plasmodium falciparum [22]. Interestingly, the
extracts of Sophora flavescens and Zingiber officinale
proved to be highly selective against the RH strain of T.
gondii [23]. These exemplary results indicate that plants
might be a valuable source of drugs against parasitic
diseases, including toxoplasmosis. Novel plant-derived
compounds might be used to replace or complement
currently used chemotherapeutic agents. Furthermore,
20-hydroxyecdysone obtained from the plant Arcangeli-
sia flava demonstrated an inhibitory effect on the
protozoan parasite Babesia gibsoni [24], the etiological
agent of babesiosis in dogs, which, like T. gondii, be-
longs to the Apicomplexa phylum. It raises a question
whether 20-hydroxyecdysone might have a similar ef-
fect on T. gondii.
Methods
Ethical approval
All experimental procedures on female (10–12 weeks old)
inbred C57BL/6 (H-2b) and BALB/c (H-2d) mice kept
under standard laboratory conditions, were conducted ac-
cording to the guidelines of the Local Ethics Commission
for Experiments on Animals in Lodz (licence number 39/
ŁB475/2009). Mice were used for the propagation of
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Toxoplasma tachyzoites and to obtain splenocytes as host
cells for in vitro parasite proliferation tests.
DX and RH Toxoplasma gondii cultivation
T. gondii tissue cysts of the low virulence DX strain (intra-
species type II) were used for mice challenge. DX strain
was maintained in C57BL/6 mice by the passage of five
brain cysts administered intraperitoneally every 2 months.
The tachyzoites of the T. gondii RH strain – intraspe-
cies type I (ATCC® Number 50174™) were maintained
through passages on female C57BL/6 and BALB/c mice
with genetically determined high and low susceptibility
(respectively) to T. gondii infection. The tachyzoites
washed out from the peritoneal cavity were expanded in
vitro on the L929 cell line (ATTC® Catalog No. CCL-1,
mouse fibroblasts) for one infection cycle. Co-cultures of
tachyzoites and host cells were cultivated in Iscove’s
Modified Dulbecco’s Medium (IMDM), supplemented
with 2 mM L-glutamine, 100 U/mL penicillin, 100 μg/mL
streptomycin, 5 × 10−5 M β-mercaptoethanol and 5 %
Fetal Bovine Serum (FBS). All commercial reagents were
purchased from Sigma-Aldrich (Poland). Extracellular par-
asites were pelleted from the culture supernatant of the
host cells, passed through a 5 μm pore filter (Sartorius,
Poland) and centrifuged (720 × g, 15 min, 24 °C).
Blood collection, processing and human peripheral blood
mononuclear cells isolation
Clinical and serological analyses were performed on a
group of 43 women and 21 men in the age range of 20–67
years (mean value 31.6 years; median 28). Only those pa-
tients who voluntarily signed a written agreement were
involved in the project. The study was approved by the
Local Committee of Ethics in Science (licence number
11 ⁄ 10 ⁄ 2005) and conducted in accordance with the
Helsinki Declaration.
Clinical specimens for the study were collected from
each patient and consisted of serum samples (used to
determine the presence of the anti-Toxoplasma IgG anti-
body) and peripheral blood samples stabilized with
EDTA (as a source of peripheral blood mononuclear
cells – PBMCs). PBMCs were isolated from the blood
samples using a Leucosept-Tube with Ficoll-Paque Plus®
(Greiner Bio-One, Germany) according to the manufac-
turer’s instructions. The final number of PBMCs was ad-
justed to 2.5 × 106 cells ⁄mL and they were used as host
cells for T. gondii in vitro proliferation tests.
Mouse splenocytes and brains isolation
Non-infected C57BL/6 mice (N = 10), BALB/c mice
(N = 14) and the ones challenged intraperitoneally
with 5 tissue cysts of the T. gondii DX strain (non-le-
thal dose) BALB/c mice (N = 10) were also used in this
study. Four weeks after the challenge and directly
prior to the experiment the animals were euthanized
and the spleens and brains were isolated.
The brain of each mouse was homogenized by 10 pas-
sages through each of 19-, 20- and 21-gauge needles and
finally suspended in 2 mL of PBS. The mean brain cyst
load was determined by counting 25 μL samples of the
homogenate under an Olympus inverted optical micro-
scope at 200 ×magnification. All samples were counted
in duplicate. Challenged mice marked as Toxoplasma-
Table 1 Metabolic activity of human PBMCs
Metabolic activity [%] of human PBMCs
24 h 48 h 72 h
Cmpd. C [μg/mL] MTT MTT [3H]-thymidine
ConA 2.5 91.62 ± 19.97 115.67 ± 24.71 *189.69 ± 42.55 *926.57 ± 169.21
α-ecdysone 2 69.76 ± 32.29 84.63 ± 25.67 76.04 ± 26.90 92.27 ± 18.25
10 89.51 ± 22.83 93.81 ± 30.35 85.59 ± 24.40 94.19 ± 19.46
20 91.97 ± 25.74 94.73 ± 23.05 97.07 ± 26.87 94.08 ± 26.97
20-hydroxy ecdysone 2 97.32 ± 20.23 97.69 ± 29.34 105.03 ± 22.52 99.21 ± 21.45
20 100.92 ± 15.48 102.92 ± 27.78 107.60 ± 20.78 100.13 ± 27.84
100 95.68 ± 15.57 102.05 ± 25.34 106.62 ± 22.18 92.71 ± 26.51
sulfadiazine 2 95.74 ± 12.74 103.15 ± 27.05 107.30 ± 26.87 91.24 ± 22.48
20 98.37 ± 18.35 104.37 ± 20.69 107.00 ± 26.21 96.23 ± 24.57
100 100.63 ± 19.82 106.38 ± 26.83 104.51 ± 21.83 89.68 ± 28.18
PBMCs isolated from individuals (N = 61) were tested in the presence of phytoecdysteroids and sulfadiazine in the concentration range between 2 and 100 μg/mL
± SD at the incubation time from 24 to 72 h. The statistically significant differences (p < 0.05) were labeled with an asterisk (*); to calculate the decrease in the
metabolic rate compared to the untreated blank, the following equation was used: viability measured using the MTT assay [%] = 100 × sample OD570 (the mean
value of the measured optical density of the test samples) / blank OD570 (the mean value of the measured optical density of the untreated cells); using the [
3H]-
thymidine test: 100 ×mean cpm incorporated into treated cells / mean cpm incorporated into cells cultured without phytoecdysteroids
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positive and non-infected mice marked as Toxoplasma-
negative were used for spleen isolation.
Single cell suspensions of splenocytes were obtained
by spleen homogenization as described in [13]. The
final spleen cells number was adjusted to 2.5 × 106 cells
⁄mL and used as host cells for T. gondii in vitro prolifer-
ation tests.
In vitro studies on human PBMC and mouse splenocytes
Cell viability assay
The effects of phytoecdysteroids on the viability of hu-
man PBMC and mouse splenocytes were evaluated using
the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide] assay. The MTT assay was used accord-
ing to international standards: ISO 10993–5:2009(E),
Biological evaluation of medical devices, Part 5: Tests for in
vitro cytotoxicity. The cells were placed into 96-well
plates (Falcon) at a density of 2.5 × 105/100 μL/well in
culture medium and 100 μL of tested phytoecdysteroids
were added to the final concentrations of: 2; 10; 20 μg/mL
of α-ecdysone (Sigma-Aldrich) or 2; 20; 100 μg/mL of
20-hydroxyecdysone (Sigma-Aldrich). Cells cultured in
the non-supplemented medium or stimulated with con-
canavalin A (ConA) (Sigma-Aldrich) at a concentration
of 2.5 μg/mL served as a negative or positive control of
proliferation, respectively. Afterwards, the cells were
exposed to the tested compounds for 24 h. Then,
1 mg/mL MTT (50 μL/well) was added to each well,
incubated at 37 ° C, 10 % CO2 for 2 h and developed as
described in [16]. The results were expressed as a via-
bility percentage compared to the 2.5 % DMSO treated
controls. All experiments were performed in triplicate.
Influence of phytoecdysteroids on PBMCs, splenocytes and
T. gondii proliferation
The human PBMC and mouse splenocytes were seeded
in triplicate at 2.5 × 105 cells per well in 96-well tissue
culture plates (Falcon) in: 100 μl of culture medium
with an equal number (5 × 105/50 μL/each well, ratio 1
: 2) of T. gondii tachyzoites or only in 150 μl of culture
medium. Then 50 μL of culture medium with tested
phytoecdysteroids was added to the final concentra-
tions of: 2; 10; 20 μg/mL of α-ecdysone (Sigma-Aldrich)
and 2; 20; 100 μg/mL of 20-hydroxyecdysone (Sigma-
Aldrich). Cells cultured in the non-supplemented
medium or stimulated with concanavalin A (ConA)
(Sigma-Aldrich) at a concentration of 2.5 μg/mL served
as a negative or positive control of proliferation, re-
spectively. The cultures were incubated at 37 °C for
48 h in humidified atmosphere with 10 % CO2 and
1 μCi of [3H]uracil (Moravek Biochemicals Inc., USA)
was then applied to each well for the last 20 h. After
the microscopic examination, the plates were frozen at
−20 °C and stored. Directly before the radioactivity
measurement, the plate was thawed and tachyzoites
and cells (PBMCs or splenocytes) were harvested with a
semiautomatic cell harvester (SKATRON Instruments,
Norway). Radioactivity (the level of 3[H] uracil incorp-
oration by toxoplasms or 3[H] thymidyne by PBMCs
and splenocytes) was measured using a 1450 Microbeta
Plus Liquid Scintillation Counter (Wallac Oy, Finland).
The cpms of control host cells (below 250/microcul-
ture) were subtracted from cpms of T. gondii infected
microcultures.
Quantitative Real-Time PCR
T. gondii genomic DNA was isolated from the tachyzoites
of the RH strain with the Wizard® SV Genomic DNA
Purification System (Promega, Madison, WI, USA) ac-
cording to the manufacturer’s instruction. The DNA
concentration and purity were measured using a Nano-
Photometer (Implen, München, Germany), while the in-
tegrity of the extracted DNA was tested using an ethidium
bromide-stained agarose gel. DNA was used for the
Table 2 Effect of phytoecdysteroids on the intensity of T. gondii proliferation in human PBMCs
Cmpd. C [μg/mL] Proliferation of parasites [%] in human PBMCs (N = 61)
Toxo-seronegative (N = 40) Toxo-seropositive (N = 21)
[3H] uracil qRT-PCR [3H] uracil qRT-PCR
α-ecdysone 2 90.59 ± 19.20 nt 86.04 ± 27.57 nt
10 105.35 ± 25.33 nt 98.06 ± 21.55 nt
20 *115.09 ± 21.26 *120.73 ± 27.06 *140.74 ± 57.33 *138.99 ± 51.02
20-hydroxy ecdysone 2 101.93 ± 23.22 nt *107.98 ± 22.54 nt
20 *117.23 ± 42.05 *122.82 ± 30.58 *111.68 ± 38.84 *109.32 ± 26.28
100 105.50 ± 32.48 nt 95.77 ± 21.85 nt
ConA 2.5 92.62 ± 29.98 nt 102.62 ± 25.35 nt
PBMCs isolated from individuals (N = 61) were tested in the presence of phytoecdysteroids and ConA in the concentration range between 2 and 100 μg/mL ± SD.
Incubation period was 72 h. The statistically significant differences (p < 0.05) were labeled with an asterisk (*). To calculate the intensity of Toxoplasma proliferation
compared to the untreated blank, the following equation was used: proliferation [%] = 100 ×mean cpm incorporated into the treated cells in the [3H] uracil test or
B1 gene in the qRT-PCR assay / mean cpm incorporated into the cultured cells or B1 gene without phytoecdysteroids
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detection and quantitation of T. gondii in analyzed sam-
ples and it was stored at −20 °C. A quantitative real-time
PCR (qRT-PCR) assay, targeting B1 gene [25] was per-
formed to detect and to quantitate T. gondii in analyzed
samples according to the modified protocol of Wahab et
al. [26]. All samples were analyzed in triplicate.
Antibody and cytokine ELISAs
The T. gondii serological status of all human sera was
checked by the determination of anti-T. gondii IgG and
IgM antibodies using commercially available ELISA kits
(NovaLisa™ IgG and NovaLisa™ IgM μ-capture; Nova-Tec
Immundiagnostica GmbH, Germany). Sera were recog-
nized as IgM-positive at NTK (NovaTec Units, NovaTec
Immundiagnostica GmbH) level >11 and IgG-positive at
>35 IU ⁄ mL. Overall, it was found that almost one-third of
the tested volunteers were infected by T. gondii and the
seroprevalence among men was slightly higher (38 %, N =
21) than among women (29 %, N = 43).
The levels of human and mice IFN-γ, IL-2, IL-4 and
IL-10 were measured in the human PBMC and mouse
splenocytes culture supernatants using commercially
available ELISA sets (OptEIA™, BD Biosciences,
Poland). The supernatants were collected at 24 h for
IL-4, 48 h for IL-2 and 72 h for IFN-γ and IL-10 from
non-infected cultures and after Toxoplasma infection.
The assays were carried out according to the manufac-
turer’s instructions. The detection limits for each cyto-
kine were as follows: 3.1 pg/mL (mouse IL-2), 4.7 pg/
mL (human IFN-γ), 7.8 pg/mL (human IL-10, mouse
IL-4) and 31.3 pg/mL (mouse IL-10 and IFN-γ).
Statistics
Statistical analysis was performed using SigmaStat 3.5
(Systat Software GmbH). The Kolmogorov-Smirnov test
was applied for assessing the normality of the data distri-
bution. The t-student or U-Mann–Whitney test was used
for comparing two groups. For multiple comparisons the
Kruskal-Wallis test or one-way ANOVA were performed.
Differences with a two-tailed value of p < 0.05 were con-
sidered as statistically significant. The best-fit IC50 curves
Fig. 1 Effect of α-ecdysone and 20-hydroxyecdysone on T. gondii proliferation in PBMCs. PBMCs from Toxo-seronegative (□) and Toxo-seropositive
(●) individuals, in the groups with observed, statistically significant (A, N = 26 and B, N = 34) and non-observed (C, N = 36 and D, N = 26) T. gondii
proliferation, in the presence of the tested compounds, after 72 h of incubation
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were plotted using GraphPad Prism 6.0 (GraphPad
Software, Inc.).
Results and Discussion
T. gondii has developed numerous mechanisms which
enable it to colonize various cell types, alter their func-
tion and use them as a reservoir of infection. While T.
gondii reproduces sexually only in feline enterocytes
[27], it uses predominantly neural and muscle cells to
survive and form tissue cysts [28]. Moreover, the para-
site hijacks blood nucleated cells turning them into Trojan
horses so that the infection disseminates throughout the
host’s organism. With consideration to the variety of hosts
and tissues which can be invaded by this parasite, two dif-
ferent cell types were chosen for the research: human per-
ipheral blood mononuclear cells (PBMCs) and murine
splenocytes. We also used two different mouse strains
characterized by low (BALB/c) and high (C57BL/6) innate
susceptibility to toxoplasmosis. Moreover, both human
and mouse cells were collected from T. gondii seronega-
tive as well as seropositive individuals.
In the first step of experiments aimed at checking the
anti-toxoplasmic activity of selected phytoecdysteroids, we
assessed the potential cytotoxicity of α-ecdysone and 20-
Fig. 2 Estimation of IC50 [μg/mL] values of sulfadiazine, pyrimethamine and hydroxyurea in T. gondii infected human PBMCs
Table 3 Effect of the studied phytoecdysteroids on the intensity of RH T. gondii proliferation
Cmpd. C [μg/mL] Proliferation of parasites [%] in mouse splenocytes
BALB/c C57BL/6
Toxo-positive (N = 10) Toxo-negative (N = 14) Toxo-negative (N = 10)
α-ecdysone 2 89.29 ± 5.90 ↓ 67.77 ± 5.05* ↓ 89.69 ± 2.54 ↓
10 91.17 ± 2.89 ↓ 10 % 75.69 ± 2.34* ↓ 39 % 99.75 ± 2.57 ↓ 13 %
20 99.29 ± 4.14 ↓ 106.63 ± 2.67* ↓ 102.58 ± 1.85 ↓
20-hydroxy ecdysone 2 88.65 ± 2.55 80.81 ± 3.35* 99.30 ± 2.55
20 88.82 ± 3.11 109.28 ± 2.11* 103.73 ± 3.94
100 90.02 ± 0.52 92.05 ± 2.34 97.76 ± 1.85
sulfadiazine 2 92.91 ± 5.11 78.34 ± 5.14* 85.79 ± 1.55*
20 94.18 ± 2.35 70.87 ± 3.11* 74.65 ± 2.48*
100 81.48 ± 1.52 65.32 ± 3.09* 62.31 ± 2.88*
ConA 2.5 192.60 ± 9.65* 151.48 ± 8.97* 191.62 ± 9.97*
Parasite proliferation was tested on splenocytes obtained from BALB/c mice previously infected with DX T. gondii (Toxo-positive), BALB/c and C57BL/6 uninfected
(Toxo-negative) mice, using [3H] uracil incorporation. The statistically significant differences (p < 0.05) were labeled with an asterisk (*); ↓ indicates an increasing
pool of protozoans with the increasing concentration of phytoecdysteroids in the splenocyte cultures
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hydroxyecdysone using the MTT assay and [3H]-thymi-
dine incorporation test. As we expected [29, 30], all cells
responded positively after stimulation with the concanava-
lin A mitogen (p < 0.05) in the control microcultures. Im-
portantly, neither phytoecdysteroids showed cytotoxic
effect on PBMCs (Table 1) nor murine splenocytes (data
not shown).
The effect of two selected phytoecdysteroids (α-ecdys-
one and 20-hydroxyecdysone) on T. gondii proliferation
was assessed by the [3H]-uracil radioisotope method, in
which the tritiated uracil is selectively incorporated into
the parasite’s nucleic acids by a highly active uracil phos-
phoribosyltransferase and uridine phosphorylase [31].
The qRT-PCR test was additionally performed to con-
firm the observation. The obtained results (Table 2)
showed that neither compound proved to have inhibi-
tory effect on T. gondii growth in human leukocyte cul-
tures. Moreover they even stimulated the tachyzoites to
proliferate. Furthermore, we observed the same
phenomenon regardless of the serological status of the
host cell donors. T. gondii proliferated more intensively
as the concentration of α-ecdysone increased and at
20 μg/mL the number of the parasite’s daughter cells in
PBMCs was higher by 15.05 ± 21.26 % (p < 0.05) for
seronegative and by 40.74 ± 57.33 % (p < 0.05) for sero-
positive individuals, compared to controls. In the case of
20-hydroxyecdysone, a significant increase in the para-
site proliferation was observed only at the concentration
of 20 μg/mL, i.e., 17.23 ± 42.05 % (p < 0.05) for seronega-
tive and 11.68 ± 18.84 % (p < 0.05) for seropositive
individuals. As shown in Table 2, these results were con-
firmed by qRT-PCR.
Due to a relatively high spread of the obtained results,
we performed a further analysis of the detailed data
(Fig. 1). The analysis led to the conclusion that within
the seronegative and seropositive individuals, two sub-
groups could be identified: individuals whose cells were
influenced by the tested compounds (Fig. 1, group A
and B) or those who did not seem to be affected (Fig. 1,
group C and D). In the groups A and B the level of para-
site proliferation in PBMCs, in the presence of the high-
est tested concentration of α-ecdysone increased by
62 % ± 32 (p < 0.05) or 81 % ± 53 (p < 0.05) compared to
the average values in seronegative and seropositive
groups, respectively. At 20 μg/mL of 20-
hydroxyecdysone a similar increase was observed, i.e.,
52 % ± 36 (p < 0.05) in seronegative and 40 % ± 17 (p <
0.05) in seropositive individuals, as compared to
controls.
It was also found that the addition of concanavalin A
to the tested cultures did not affect the final level of T.
gondii proliferation; most likely because the host cells
were unable to respond to a mitogen as quickly as the
invasion of the parasites occurred. For comparative
purposes we tested parallelly three different chemical
agents able to restrict RH T. gondii growth: sulfadiazine
and pirymethamine (used as recommended drugs in
the therapy of toxoplasmosis) as well as hydroxyurea
(used in anti-tumor therapy or in research) as a posi-
tive controls. In Fig. 2 we present the IC50 values for
Table 4 Cytokine profiles corresponding to human PBMCs cultured in the presence of phytoecdysteroids or concanavalin A
Cytokine levels [pg/mL]
PBMCs control α-ecdysone 20-hydroxyecdysone ConA
IFN-γ
0 2 10 20 2 20 100 2.5
A. mean 126.75 132.52 129.92 125.68 127.04 124.58 131.26 2 661.02*
N = 52 SD 106.20 121.25 114.94 114.31 123.67 116.29 127.42 1197.77
median 118.26 127.32 120.45 121.71 120.44 122.88 212.62 2 238.19
B. mean 11.96 7.85 10.86 11.23 7.12 7.74 9.96 1003.35*
N = 8 SD 10.16 1.94 4.32 4.25 1.57 0.97 5.04 414.06
median 7.21 7.97 9.32 9.63 7.07 7.75 7.51 107.77
IL-10
A. mean 240.76 255.75 297.50 311.00 255.81 296.75 301.58 2758.74*
N = 48 SD 206.93 202.64 236.93 253.40 183.88 183.35 243.97 1075.34
median 143.54 209.02 199.84 286.51 254.64 286.36 327.35 2849.68
B. mean 13.12 8.56 8.66 7.23 9.89 8.93 11.30 606.68*
N = 9 SD 3.09 1.39 2.25 1.50 2.43 3.95 7.10 196.97
median 13.00 8.79 8.79 7.60 10.57 7.90 8.79 574.96
PBMCs were derived from individuals who responded (A) or did not respond (B) to phytoecdysteroids. The statistically significant differences (p < 0.05) were
labeled with an asterisk (*)
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sulfadiazine (IC50 = 2495.91 μg/mL), pyrimethamine
(IC50 = 14.69 μg/mL) and hydroxyurea (IC50 = 4.74 μg/
mL) against RH T. gondii proliferating in normal hu-
man cells (PBMCs) at the parasite-host cell ratio of 2:1.
Numerous studies proved that T. gondii susceptibility
to a drug depends both on the invading strain and the
host cells to be infected. Using the RH strain and dif-
ferent normal host cells, i.e., human MRC-5 [32], Vero
[33], HFF [34] the IC50 values of sulfadiazine ranged
from 2.5 to 77 μg/mL. In contrast to this, the use of
human carcinoma HEp-2 [35] or HeLa [36] cells chan-
ged the IC50 to, 600–700 or >1000 μg/mL, respectively.
As our observations reveal, the determination of the
IC50 for a certain parasite strain is closely related to
the type of host cells and also to the parasite load used.
In order to verify the obtained results the same experi-
ments on two strains of inbred mice, characterized by
low (BALB/c) or high (C57BL/6) innate susceptibility to
T. gondii infection were performed. We analyzed the ef-
fect of phytoecdysteroids on the parasite proliferation in
murine splenocytes derived from both uninfected and T.
gondii-infected animals. Chronic toxoplasmosis was in-
duced by a challenge with the DX strain and the pres-
ence of tissue cysts in brains of infected mice was
confirmed microscopically just before the isolation of
spleen cells. The parasite load ranged from 450 to 600
cysts per brain. We observed that the intensity of para-
site proliferation in host cells collected from both mouse
strains correlated with the increasing concentration of
α-ecdysone; however, only in the case of the group of
uninfected BALB/c mice the proliferation increase was
statistically significant (38.86 %, p < 0.05; Table 3).
Ecdysteroids have been reported to exhibit a wide
array of positive pharmacological effects on mammals,
including carbohydrate, lipid and protein metabolism.
Hence, multiple ecdysteroid-containing preparations are
already commercially available, for instance as dietary
supplements for sportsmen. Since ecdysteroids are con-
sidered as potential therapeutic drugs, it is essential to
determine their effect on various pathogens. In general,
the impact of phytoecdysteroids on parasites is poorly
understood and does not explain the mechanisms of
their action, which appears to vary in different parasites.
While 20-hydroxyecdysone showed a significant inhib-
ition of another apicomplexan parasite Babesia gibsoni
[24], our results surprisingly demonstrated that phytoec-
dysteroids did not inhibit, but even promoted the multi-
plication of Toxoplasma gondii both in the human and
murine immunocompetent cells. These observations are
reflected by literature data referring to parasites such as
Trypanosoma cruzi, which cause trypanosomiasis (Cha-
gas disease) in humans and animals [37]. Barker et al.
[38] reported that ecdysone can play a hormonal role in
filarial worms similar to that found in insects. Namely,
ecdysone was found to stimulate the microfilarial release
in Brugia pahangi (a filarial worm of dogs and cats) and
to control the meiotic reinitiation in the oocytes of Diro-
filaria immitis (a roundworm spread by mosquitoes). It
has been also demonstrated that Onchocerca volvulus
and Onchocerca lienalis microfilariae increase their





control α-ecdysone 20-hydroxyecdysone ConA
IFN-γ
0 2 10 20 2 20 100 2.5
A. mean 579.94 668.42 644.86 601.85 612.61 603.78 615.51 1040.90*
N = 49 SD 552.02 541.49 515.38 500.54 540.02 524.31 522.29 543.24
median 362.98 441.04 448.27 494.70 464.31 422.97 492.39 941.43
B. mean 58.30 91.36 79.17 74.69 67.42 64.34 75.88 171.39*
N = 10 SD 35.80 65.93 50.10 46.09 35.78 40.41 50.66 68.67
median 61.19 68.31 71.24 83.38 65.14 59.40 75.96 163.96
IL-10
A. mean 622.90 542.24 616.43 706.24 608.92 660.99 623.21 728.45
N = 46 SD 309.04 338.16 292.83 350.71 311.57 309.01 328.14 589.63
median 521.62 455.37 491.01 566.36 562.35 523.13 500.08 681.18
B. mean 68.94 46.73 65.46 81.36 51.35 57.03 62.39 88.98
N = 12 SD 51.28 33.14 44.68 46.89 31.61 41.42 45.79 51.47
median 41.48 38.49 40.54 56.04 40.38 37.97 39.59 68.94
PBMCs were derived from individuals who responded (A) or did not respond (B) to phytoecdysteroids. The statistically significant differences (p < 0.05) were
labeled with an asterisk (*)
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metabolic activity when treated in vitro with 20-
hydroxyecdysone [39]. In the light of these observations,
it is particularly important to consider the effect of
ecdysteroids on immunocompromised patients, such as
HIV-infected individuals, which are in a particular dan-
ger of developing a superinfection. Analogously to HIV-
associated toxoplasmosis, patients infected with human
T-cell leukaemia virus type I (HTLV-1) develop fre-
quently a severe strongyloidiasis caused by a nematode
Strongyloides stercoralis [40]. Although the moulting
process in parasitic nematodes is very complex being
possibly regulated by more than one transcriptional cas-
cade, there is evidence that steroids, including ecdyster-
oids, may up-regulate the moulting signalling within the
S. stercoralis larvae and it might be caused by a presence
of a nuclear hormone receptor of the steroid/thyroid
hormone-receptor superfamily [41, 42].
Ecdysteroids display hormonal function in insects
(moulting hormones). However, their pharmacological
effects on humans and animals cannot be simply consid-
ered as hormonal activity. The use of phytoecdysteroids
in humans and animals has been proposed on the basis
of their supposed interference with steroidal metabolic
pathways of mammals. While the main focus remains on
estrogenic and anabolic effects in humans [43] and do-
mestic animals [44, 45], little has been published on
these compounds’ immunomodulatory and anti-
inflammatory potential. Trenin and Volodin [46] de-
scribed 20-hydroxyecdysone as a human lymphocyte and
neutrophil modulator. 20-hydroxyecdysone was also re-
vealed to modulate the fluoride-stimulated respiratory
burst of human neutrophils in the same manner as
water soluble antioxidants. Moreover, 20-
hydroxyecdysone dramatically attenuated renal injury
in diabetes model. The authors concluded that 20-
hydroxyecdysone might act through suppressing post-
receptor signalling of TGF-β1. [47]. On the contrary,
Harmatha et al. [48] found that 20-hydroxyecdysone
did not influence the intensity of nitric oxide biosyn-
thesis in mouse resident peritoneal macrophages stimu-
lated by interferon-γ, and lipopolysaccharide. Similarly,
Tanaguchi et al. [49] also did not observe any anti-
inflammatory effect of 20-hydroxyecdysone in rats.
Data obtained by Peschel et al. [50] in the HeLa-IL-6
Table 6 Cytokine profiles corresponding to the mice splenocytes cultivated in the presence of phytoecdysteroids and concanavalin A
Cytokine levels [pg/mL]
Splenocytes control α-ecdysone 20-hydroxyecdysone ConA
IFN-γ
0 2 10 20 2 20 100 2.5
BALB/c mean 752.33 606.89 552.24 667.61 716.58 709.40 663.52 1997.97*
N = 12 SD 634.53 423.51 438.02 599.92 452.11 568.89 409.02 369.25
negative median 48.28 566.79 498.71 632.57 666.49 657.71 565.57 1857.23
BALB/c mean 1735.99 1000.17 1168.71 1057.95 1540.23 1661.91 1560.54 4307.02*
N = 9 SD 714.81 687.62 843.80 901.84 572.05 604.58 633.65 82.08
positive median 1848.28 878.07 976.23 819.85 1385.37 1485.31 1439.19 4292.66
IL-10
BALB/c mean 19.49 20.84 18.87 19.60 21.39 19.20 20.54 1987.46*
N = 12 SD 9.08 13.12 7.80 10.45 8.12 8.85 9.55 340.02
negative median 16.30 18.58 16.08 17.56 19.86 17.48 18.96 1883.19
BALB/c mean 1344.07 1351.45 1385.59 1426.28 1550.71 1390.64 1437.98 2531.09*
N = 9 SD 583.19 543.89 550.90 522.69 506.47 494.77 521.20 661.58
positive median 972.59 975.12 1006.89 1084.91 1228.71 1158.47 1079.78 2878.76
IL-2
BALB/c mean 11.58 9.85 9.04 9.64 9.54 10.63 9.71 159.12*
N = 10 SD 9.76 2,55 3.32 3.21 3.82 3.79 3.23 30.02
negative median 10.03 8.01 7.96 7.86 7.32 8.56 8.56 143.45
BALB/c mean 16.22 21.82 15.88 19.91 19.31 19.80 20.98 276.97*
N = 10 SD 10.25 11.48 8.83 13.63 15.55 12.89 13.42 42.75
positive median 15.25 17.77 14.25 16.45 13.55 15.50 19.05 290.12
Splenocytes were derived from BALB/c mice uninfected (T. gondii-seronegative) and chronically infected with T. gondii DX strain (T. gondii-seropositive). The
statistically significant differences (p < 0.05) were labeled with an asterisk (*)
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model (cells stably transfected with an IL-6-bound re-
porter gen) implied a 20-hydroxyecdysone caused in-
hibition of nuclear factor - kappa B (NF-κB), which
plays a central role in cellular immune response, in-
flammation and cell fate. The situation is different
when standard human epithelial cells are infected with
intracellular parasite such as T. gondii. Kim et al. [51]
reported that T. gondii RH strain infected HeLa cells
induced NF-κB and increased the expression of two
chemokines: IL-8 and monocyte chemotactic protein-1
(MCP-1) mRNA. Moreover, the addition of IL-1α to T.
gondii cultures increased the activation of NF-κB and
IL-8 transcriptional reporters, compared to tachyzoite-
infected cells without IL-1α treatment. However, the
described phenomenon is not unequivocal because
various studies showed that Toxoplasma has developed
many strategies that can modulate the host NF-κB
pathway. Evidence currently exists for both inhibition
[52, 53] or activation [54–57] of the NF-κB pathway in
host cell infected by Toxoplasma resulting in sup-
pressed proinflammatory cytokine expression and en-
hanced survival of the pathogen or inhibition of
Table 7 Cytokine profiles corresponding to the splenocytes infected by T. gondii and cultivated in the presence of




control α-ecdysone 20-hydroxyecdysone ConA
IFN-γ
0 2 10 20 2 20 100 2.5
BALB/c mean 1776.41 1748.22 1809.40 1263.67* 1431.23 908.90* 1860.88 2236.53*
N = 14 SD 672.75 452.11 568.89 109.02 760.64 200.90 1275.54 469.06
negative median 1626.60 1666.49 1884.71 1265.57 1303.56 898.47 1854.40 1952.70
BALB/c mean 2081.82 2983.11 2907.12 2912.51 2965.06 2884.66 2950.60 4159.40*
N = 10 SD 1253.55 1390.12 1445.01 1497.61 1541.11 1531.37 1477.52 322.44
positive median 1604.36 3972.21 3812.13 3954.39 4070.46 3987.08 3984.11 4198.95
C57Bl/6 mean 816.88 790.06 749.12 827.65 639.40 652.87 765.19 3569.88*
N = 10 SD 326.21 278.98 237.76 232.67 232.76 245.14 219.75 378.49
negative median 787.18 698.90 678.65 743.09 606.98 120.28 136.92 3339.78
IL-10
BALB/c mean 534.73 531.39 538.11 639.41 631.99 535.42 631.71 1987.46*
N = 14 SD 369.76 367.85 317.15 411.98 310.57 410.32 418.65 440.02
negative median 532.30 531.08 532.00 636.93 629.86 533.53 528.94 2083.19
BALB/c mean 1836.67 2054.01 1783.78 1907.01 2252.42 1981.89 1942.38 3157.88*
N = 10 SD 387.73 579.95 716.93 499.15 592.62 392.76 433.08 1186.99
positive median 1638.48 1952.01 1540.04 1691.38 1946.47 1760.87 1821.10 3615.60
C57Bl/6 mean 28.73 30.68 33.36 28.94 29.59 31.75 25.98 516.83*
N = 9 SD 20.33 24.72 27.19 19.04 17.88 16.70 19.85 378.49
negative median 25.46 28.56 29.46 25.98 26.58 29.87 34.56 501.78
IL-2
BALB/c mean 22.98 20.22 20.69 23.24 21.45 26.25 24.47 163.68*
N = 10 SD 20.69 19.85 19.87 18.23 16.59 20.69 20.58 54,76
negative median 21.20 20.30 19.58 19.23 19.96 19.65 22.87 139.78
BALB/c mean 124.42 151.08 130.26 140.97 149.61 146.26 166.44 339.63*
N = 10 SD 69.58 64.59 56.79 56.89 76.40 72.27 69.21 14.84
positive median 87.18 120.20 116.25 125.37 131.56 120.28 136.92 339.78
C57Bl/6 mean 12.54 10.02 10.17 10.29 11.42 12.26 11.87 163.68*
N = 10 SD 10.70 9.08 9.57 8.92 6.38 10.84 10.10 54,76
negative median 10.25 10.00 9.25 9.98 10.25 10.24 10.36 139.78
Splenocytes were derived from uninfected (T. gondii-seronegative) BALB/c or C57BL/6 as well as from chronically infected with T. gondii DX strain (T. gondii-
seropositive) BALB/c mice. The statistically significant differences (p < 0.05) were labeled with an asterisk (*)
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apoptosis, an important defence mechanism against
intracellular pathogens. The described results were
dependent for example on whether in vivo or in vitro
conditions were analyzed [53], what type of strain and
techniques were used in the experiments. For example,
infection with type I strain inhibited the NF-κB path-
way and down-regulated the production of IL-12, thus
limiting protective T helper 1(Th1)-type cytokine (IFN-
γ, IL-2) response [52, 58] while Toxoplasma type II par-
asites activated the NF-κB p65 subunit [54]. It was con-
firmed that the observed differences were related to the
various expression levels of ROP18 [52] or GRA15 [54]
proteins, being some of the crucial antigens in Toxo-
plasma pathogenesis.
In the next step of our study the concentrations of cru-
cial protective cytokines in T. gondii infection, IFN-γ, IL-2
and IL-10, were quantified in the post-culture supernatants
of the human PBMCs (Tables 4 and 5) and mouse spleno-
cytes (Tables 6 and 7) infected with T. gondii (Tables 5 and
7, respectively) or non-infected (Tables 4 and 6, respect-
ively), and cultivated in the presence of phytoecdysteroids
in the concentration range of 2–100 μg/ml (Tables 4, 5, 6
and 7). Treatment of human (Table 4) and mouse (Table 6)
host cells with both tested ecdysteroids did not signifi-
cantly change their secretory activity and the levels of
IFN-γ and IL-2 as well as IL-10 were similar in cultures
supplemented with ecdysteroids as compared to adequate
controls without the compounds. The same results were
observed in human PBMCs (Table 5) and mouse spleno-
cytes (Table 7) infected in vitro by T. gondii RH tachy-
zoites. The host status: infected (BALB/c mice) vs. non-
infected (BALB/c and C57BL/6 mice) (Tables 6 and 7) and
phytoecdysteroids responder (humans, group A) vs. non-
responder (humans, group B) (Table 4 and 5) did not ap-
pear to be important factors influencing cytokines secre-
tion. But comparison of cytokine levels in control cultures
of uninfected and not stimulated with phytoecdysteroids
(Tables 4 and 6) vs. Toxoplasma infected and not stimu-
lated with phytoecdysteroids host cells shows that T.
gondii RH strain aroused IFN-γ and IL-10 production (Ta-
bles 5 and 7). This result is consistent with another obser-
vation that in vitro infection with type I strain did not
inhibit NF-κB p65 but activated c-Rel nuclear transloca-
tion [54], an important host additional signaling pathway
in the regulation of inflammatory, immune, and anti-
apoptotic responses. The simultaneous presence of an-
other stimulator such as phytoecdysteroids did not affect
the cytokines release. According to our results presented
in Tables 4, 5, 6 and 7, the tested phytoecdysteroids alone
or in Toxoplasma co-cultures did not stimulate the in
vitro secretion of the essential cytokines, either by human
or by murine immune cells involved in an effective intra-
cellular killing of the parasite. It is highly probable that, as
in the case of HeLa [50], phytoecdysteroids inhibit NF-κB
which is required for the production of cytokines such as
IFN-γ or IL-12 [59]. The observed lack of Toxoplasma
proliferation in human PBMCs in the presence of ConA
(Table 2) correlated with the lack of IL-10 production but
concomitantly with a statistically significant increase in
IFN-γ level (Table 5). Interestingly, only in the phytoec-
dysteroids concentration of 20 μg/mL (Table 7), the levels
of IFN-γ in the cultures of T. gondii-infected spleen cells
derived from T. gondii-negative BALB/c mice were signifi-
cantly lower (p < 0.05) than in controls and in other test
cultures supplemented with ecdysteroids. Lower levels of
IFN-γ were associated with higher parasite proliferation
(Table 3).
Conclusions
Judging by the effect of phytoecdysteroids on the T. gon-
dii proliferation, demonstrated for the first time in this
study, it seems that these compounds should not be
taken into consideration as potential medications to
treat toxoplasmosis. Phytoecdysteroids included in the
food are most likely not harmful for human or animal
health but certain nutrients containing ecdysteroids at
high concentrations could promote T. gondii prolifera-
tion in chronically infected and immunocompromised
Fig. 3 Graphical Conclusions
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individuals. In order to assess the real impact of ecdys-
teroids on the course of natural T. gondii invasion, in
vivo research should be undertaken because it cannot be
ruled out that the in vivo effect will be different than the
in vitro one. However, taking into account the possible
stimulating effect of ecdysteroids on some opportunistic
parasites (such as Toxoplasma or Strongyloides) further
studies are necessary and should focus on the mecha-
nisms of their action, which directly or indirectly en-
hance the parasite growth. Since ecdysteroids are
considered as potential drugs, it is essential to determine
their effect on various parasitic pathogens, which may
infect the host at the same time, especially in immuno-
compromised individuals (Fig. 3).
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